Cardiovascular adverse effects of newer antidepressants

被引：37

作者：

Mago, Rajnish ^{[1
]}

Tripathi, Neeta ^{[2
]}

Andrade, Chittaranjan ^{[3
]}

机构：

[1] Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat & Human Behav, Mood Disorders Program, Philadelphia, PA 19107 USA

[2] Hamilton Cardiol Associates, Hamilton, NJ USA

[3] Natl Inst Mental Hlth & Neurosci, Dept Psychopharmacol, Bangalore 560029, Karnataka, India

来源：

EXPERT REVIEW OF NEUROTHERAPEUTICS | 2014年 / 14卷 / 05期

关键词：

electrocardiogram; antidepressants; selective serotonin reuptake inhibitors; adverse effects; side effects; blood pressure; orthostatic hypotension; QT interval; cardiovascular; serotonin-norepinephrine reuptake inhibitors; MAJOR DEPRESSIVE DISORDER; SEROTONIN-REUPTAKE INHIBITORS; QT INTERVAL PROLONGATION; PLACEBO-CONTROLLED TRIAL; ISCHEMIC-HEART-DISEASE; BLOOD-PRESSURE; DOUBLE-BLIND; SAFETY PROFILE; 5-HYDROXYTRYPTAMINE RECEPTORS; CORONARY-ARTERY;

D O I：

10.1586/14737175.2014.908709

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Newer antidepressants that are more selective in their neurotransmitter effects include the selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and others (agomelatine, bupropion, mirtazapine, reboxetine, vilazodone, vortioxetine). This article systematically reviews data from a variety of sources regarding the potential adverse effects of these medications on various cardiovascular parameters. Potential biochemical mechanisms by which these antidepressants may adversely affect the cardiovascular system are also discussed. Antidepressants that are associated with higher cardiovascular risk (SNRIs, reboxetine), lower risk (SSRIs), and without current evidence of cardiovascular risk (agomelatine, mirtazapine, vilazodone, vortioxetine) are identified. The FDA's recommendations regarding citalopram are organized and summarized, and situations with higher risk of cardiovascular adverse effects are identified.

引用

页码：539 / 551

页数：13

共 103 条

[1]

Abdelmawla AH, 1999, BRIT J CLIN PHARMACO, V48, P345

[2] Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data [J].

Agelink, MW ;

Ullrich, H ;

Baumann, B ;

Strum, S ;

Majewski, T .

PSYCHOPHARMACOLOGY, 2002, 163 (02) :151-156

[3] Blood pressure changes during short-term fluoxetine treatment [J].

Amsterdam, JD ;

Garcia-Espana, F ;

Fawcett, J ;

Quitkin, FM ;

Reimherr, FW ;

Rosenbaum, JF ;

Beasley, C .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (01) :9-14

[4]

Andrade C., 2014, J CLIN PSYC IN PRESS, P75

[5] Drug Interactions in the Treatment of Depression in Patients Receiving β-Blocker Drugs [J].

Andrade, Chittaranjan .

JOURNAL OF CLINICAL PSYCHIATRY, 2013, 74 (01) :E75-E78

[6]

Andrade C, 2012, J CLIN PSYCHIAT, V73, P1322, DOI [10.4088/JCP.12f07977, 10.4088/JCP.12f08124, 10.4088/JCP.12f07731, 10.4088/JCP.12f07732, 10.4088/JCP.12f08054, 10.4088/JCP.12f08248, 10.4088/JCP.12f07726]

[7] Serotonin Reuptake Inhibitor Antidepressants and Abnormal Bleeding: A Review for Clinicians and a Reconsideration of Mechanisms [J].

Andrade, Chittaranjan ;

Sandarsh, Surya ;

Chethan, Kumar B. ;

Nagesh, Koregala S. .

JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (12) :1565-1575

[8]

[Anonymous], 2011, PRISTIQ DESVENLAFAXI

[9] Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study [J].

Bakish, David ;

Bose, Anjana ;

Gommoll, Carl ;

Chen, Changzheng ;

Nunez, Rene ;

Greenberg, William M. ;

Liebowitz, Michael ;

Khan, Arif .

JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2014, 39 (01) :40-49

[10] Bupropion exposures: Clinical manifestations and medical outcome [J].

Belson, MG ;

Kelley, TR .

JOURNAL OF EMERGENCY MEDICINE, 2002, 23 (03) :223-230

← 1 2 3 4 5 6 7 8 9 10 →